Filtered By:
Condition: Hemorrhagic Stroke
Vaccination: Vaccines
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 80 results found since Jan 2013.
Intracranial aneurysm rupture within three days after receiving mRNA anti-COVID-19 vaccination: Three case reports
CONCLUSION: Although the advantages of COVID-19 vaccination appear to outweigh the risks, pharmacovigilance must be maintained to monitor potentially fatal adverse events and identify possible associations.PMID:35509565 | PMC:PMC9062907 | DOI:10.25259/SNI_1144_2021
Source: Surgical Neurology International - May 5, 2022 Category: Neurosurgery Authors: Sotaro Oshida Yosuke Akamatsu Yoshiyasu Matsumoto Taro Suzuki Takuto Sasaki Yuki Kondo Shunrou Fujiwara Hiroshi Kashimura Yoshitaka Kubo Kuniaki Ogasawara Source Type: research
Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
In conclusion, this review has concisely summarized the current rare adverse events related and unrelated to BNT162b2, arguably for the first time in sufficient depth, to better communicate vaccine safety to the public.PMID:35891231 | DOI:10.3390/vaccines10071067
Source: Herpes - July 27, 2022 Category: Infectious Diseases Authors: Shin-Jie Yong Alice Halim Michael Halim Abbas Al Mutair Saad Alhumaid Jehad Al-Sihati Hawra Albayat Mohammed Alsaeed Mohammed Garout Reyouf Al Azmi Noor Aldakheel Abeer N Alshukairi Hani A Al Ali Adel A Almoumen Ali A Rabaan Source Type: research
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease
DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2.PMID:36284639 | PMC:PMC9585384 | DOI:10.1002/rth2.12814
Source: Thrombosis and Haemostasis - October 26, 2022 Category: Hematology Authors: Erika Tarasco Anne Sophie von Krogh Radomira Hrdlickova Thomas R Braschler Teresa Iwaniec Paul N Kn öbl Eriko Hamada Oleg Pikovsky Stefan Farese Odit Gutwein Petr Kessler Nina H Schultz Charis von Auer Jerzy Windyga Kenneth Friedman Ingrid Hrachovinova J Source Type: research
A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan
CONCLUSION: The findings suggested that the COVID-19 mRNA vaccine was generally safe, whilst a signal of pulmonary embolism following the first dose of the COVID-19 mRNA vaccine was observed.PMID:36371366 | DOI:10.1016/j.vaccine.2022.10.088
Source: Vaccine - November 12, 2022 Category: Allergy & Immunology Authors: Yoshinori Takeuchi Masao Iwagami Sachiko Ono Nobuaki Michihata Kohei Uemura Hideo Yasunaga Source Type: research
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research
